Pharmacotherapy of Muscle Dystrophies
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 346
Special Issue Editor
Special Issue Information
Dear Colleagues,
Muscular dystrophies involve a large list of primary diseases due to mutations in more than 70 specific genes, which result in the observation of dystrophic changes in different muscles. In other words, degenerated muscle is usually replaced by fibrous tissues unable to perform normal muscle function. Importantly, in several cases, is not only the skeletal muscle affected, but also other tissues, such as the heart, eyes, spine, endocrine glands, brain, etc. Given the numerous genetic defects identified today, as well as our improved understanding of the pathogenesis of some of these diseases, novel therapeutic approaches have been developed. From the large list of muscular dystrophy diseases, only Duchenne muscular dystrophy has recently achieved approval for a few personalized therapies, with the rest of the diseases in different position through the drug development pathway. In this Special Issue, we concentrate on assembling examples of therapeutic opportunities and developments for some of the diseases into the group of muscular dystrophy conditions.
This Special Issue of Pharmaceuticals, entitled “Pharmacotherapy of Muscle Dystrophies”, will cover a selection of research topics related to recent advances in the mechanisms of muscular dystrophies, as well as novel therapeutic approaches. Experimental papers, commentaries, and up-to-date review articles are all welcome.
Dr. Arturo López Castel
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- muscular dystrophy
- therapy
- skeletal muscle
- pharmacologic development
